Description
Product Overview / 商品概要
Bestron Ophthalmic Solution 0.5% (ベストロン点眼用0.5%)
Generic: Cefmenoxime Hydrochloride / セフメノキシム塩酸塩
Therapeutic Category: Cephalosporin Antibiotic Preparation / セフェム系抗生物質製剤
Manufactured by: Senju Pharmaceutical Co., Ltd. / 千寿製薬株式会社
Composition & Specification / 組成・規格
Active Ingredient: Cefmenoxime Hydrochloride 25mg (potency) per vial (powder); Cefmenoxime Hydrochloride 5mg (potency) per 1mL after reconstitution with supplied diluent / 粉末1瓶中 セフメノキシム塩酸塩25mg(力価)/添付の溶解液に溶解後1mL中 セフメノキシム塩酸塩5mg(力価)
Additives: Powder: Dried sodium carbonate / Diluent: Sodium hydrogen phosphate hydrate, Sodium dihydrogen phosphate hydrate, Boric acid, Sodium edetate hydrate, Methyl parahydroxybenzoate, Propyl parahydroxybenzoate, Tonicity agent / 粉末:乾燥炭酸ナトリウム/溶解液:リン酸水素ナトリウム水和物、リン酸二水素ナトリウム水和物、ホウ酸、エデト酸ナトリウム水和物、パラオキシ安息香酸メチル、パラオキシ安息香酸プロピル、等張化剤
Appearance: Powder: White to pale orange-yellow sterile powder / Diluent: Colorless clear sterile solution / After reconstitution: Colorless to pale yellow clear aqueous ophthalmic solution, pH 6.0–8.0
外観: 粉末:白色~帯橙淡黄色の無菌の粉末/溶解液:無色澄明の無菌溶液/溶解後:無色~淡黄色澄明の水性点眼剤、pH 6.0~8.0
Indications / 効能効果
EN: Susceptible organisms: Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Moraxella lacunata (Morax-Axenfeld bacillus), Serratia marcescens, Proteus spp., Morganella morganii, Providencia spp., Haemophilus influenzae, Haemophilus aegyptius (Koch-Weeks bacillus), Pseudomonas aeruginosa, Cutibacterium acnes / Indications: Blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), perioperative ophthalmic antiseptic therapy
JA: 〈適応菌種〉セフメノキシムに感性のブドウ球菌属、レンサ球菌属、肺炎球菌、モラクセラ・ラクナータ(モラー・アクセンフェルト菌)、セラチア・マルセスセンス、プロテウス属、モルガネラ・モルガニー、プロビデンシア属、インフルエンザ菌、ヘモフィルス・エジプチウス(コッホ・ウィークス菌)、緑膿菌、アクネ菌/〈適応症〉眼瞼炎、涙嚢炎、麦粒腫、結膜炎、瞼板腺炎、角膜炎(角膜潰瘍を含む)、眼科周術期の無菌化療法
Dosage and Administration / 用法用量
EN: Dissolve with the supplied diluent to a concentration of 5mg (potency) of Cefmenoxime Hydrochloride per 1mL. Usually instill 1 to 2 drops at a time, 4 times daily. The frequency may be adjusted according to symptoms. Do not continue administration for a prolonged period without clear improvement in symptoms.
JA: 本剤を添付の溶解液で1mL当たりセフメノキシム塩酸塩として5mg(力価)の濃度に溶解し、通常1回1~2滴を1日4回点眼する。なお、症状により適宜回数を増減する。ただし、症状に改善がみられない場合は漫然と長期間の連続投与を行わないこと。
Contraindications / 禁忌
EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者
Regulatory Information / 規制情報
Approval No.: 21900AMX01095
Sales Started: February 1988 / 1988年2月
Classification Code: 871317
Storage: Store at room temperature / 室温保存
Shelf Life: 2 years / 2年
Packaging / 包装
Main Package (for sale): 1 vial (25mg (potency)) with plastic diluent container 5mL x 5 sets / 〔1瓶(25mg(力価))・プラスチック溶解液容器5mL〕×5
Other Available Packages (by special order): 1 vial (25mg (potency)) with plastic diluent container 5mL x 5 sets
Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.




Reviews
There are no reviews yet.